Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027
Redding,California, Oct. 21, 2021 (GLOBE NEWSWIRE) -- According to a new market research report Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027, published by Meticulous Research, the plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to reach $41.4 billion by 2027.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117
Plasma fractionation is a process of separation, extraction, and purification of specific components from the plasma. Recently, the growing number of chronic cases with aged people has increased the demand for plasma-derived products. In the case of aged people, but in inborn, immunological disorders have increased over the past few years. For instance, the number of genes identified with inborn errors of immunity was 269 in 2015, which increased to 430 in 2019. Thus, the demand for plasma-derived immunoglobulins and other products is rising at a rapid pace.
COVID-19 Impact on the Plasma Fractionation Market
The outbreak of COVID-19 forced countries to undertake initiatives to adopt plasma therapy. For instance, the European Commission, DG DIGIT, developed and hosted a database in compliance with Data Protection Regulations 2016/679 and 2018/17/25 to support the monitoring of convalescent plasma donation and use monitoring. The database was designed in collaboration with the European Blood Alliance (EBA). The EBA was responsible for coordinating the data entry by all blood establishments across the EU.
Story continues
Apart from government initiatives, companies are also developing an effective treatment against COVID-19. For instance, Octapharma AG (Switzerland) launched a special project team to explore new therapies for COVID-19. The company also announced that it had joined other plasma fractionation leaders to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19. In February 2020, Grifols, S.A. (Spain) agreed with the Public Investment Fund of Saudi Arabia (PIF) to build a network of plasma collection centers and other facilities for producing plasma medicines, including a plasma fractionation plant a purification plant in Saudi Arabia.
Thus, plasma-derived immunoglobulin played an important role in the treatment of the disease, thus created a positive impact on the growth of the plasma fractionation market.
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5117
The plasma fractionation market is segmented on the basis of product [Immunoglobulins (IVIG, SCIG, and others), coagulation factors, albumin, protease inhibitors, and others), application (immunology, hematology, neurology, critical care, hemato-oncology, rheumatology, and others), end user (hospitals & clinics, clinical research laboratories, and academic institutes), and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.
Based on product type, the immunoglobulins accounted for the largest share of the overall plasma fractionation market in 2020. Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. The most common use of immunoglobulin therapy is to treat primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being considered for various neurological diseases, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome. The large share of this segment is attributed to the rising adoption of SCIg and the increasing on- and off-label use of immunoglobulins for various indications.
Based on application, the neurology segment commanded the largest share of the overall plasma fractionation market in 2020. The rising number of neurological disorders and the focus of vendors on discovering plasma products for neurology.
Based on end user, the hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020. The growing need for therapies for immunodeficiency disorders, growing number of hospitals & healthcare expenditure, and rising consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.
Quick Buy Plasma Fractionation Research Report: https://www.meticulousresearch.com/Checkout/17799149
Based on geography, in 2020, the North America accounted for the largest share of the global plasma fractionation market. On the other hand, Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the APAC plasma fractionation market are rising consumption of plasma-derived products, presence of leading players, contract fractionation agreements between countries, and programs for increasing the use of plasma and fractionation.
The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry over the past four years. The plasma fractionation market witnessed several new product launches, approvals, agreements, partnerships & collaborations, expansions, and acquisitions in recent years. For instance, in April 2020, Grifols, S.A. (Spain) launched HyperRAB (3-mL 900-IU). It will be used for treatment for rabies post-exposure prophylaxis.
Some of the key players operating in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octopharma AG (Switzerland), Kedrion S.P.A. (Italy), Shire plc (U.K.), Biotest AG (Germany), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Ltd (U.K.), Japan Blood Products Organization (Japan), SeraCare Life Sciences, Inc. (U.S.), Haemonetics Corporation (U.S.),BioIVT LLC (U.S.), Green Cross Biotherapeutics Inc. (Canada), Sartorius Stedim Biotech GmbH (Germany), LFB S.A. (France), Scinomed Ltd. (U.K.), Oxbridge Pharma Ltd (U.K.), Sanquin (Netherlands), Shanghai Institute of Biological Products Co., Ltd. (China), Hualan Biological Engineering Inc (China), Walvax Biotechnology Co., Ltd. (China), Shanxi Kangbao Biological Product Co. Ltd. (China), Sichuan YuandaShuyang Pharmaceutical Co., Ltd. (China), Reliance Life Sciences (India), IntasBiopharm Pharmaceuticals Ltd. (India), Hemarus (India), Japan Blood Products Organization (Japan), Chemo-Sero Therapeutic Research Institute (Japan), SK Plasma Co., Ltd. (Korea), Korean Red Cross (Korea), STROVI (Malaysia), The National Bioproducts Institute (South Africa), Kamada Ltd. (Israel), MDA Plasma Fractionation Center (Israel), and Hemobras (Brazil) among others.To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/plasma-fractionation-market-5117
Scope of the Report:
Plasma Fractionation Market, by Product
Immunoglobulins
Coagulation Factors
Albumin
Protease Inhibitors
Others
Plasma Fractionation Market, by Application
Immunology
Hematology
Neurology
Critical Care
Hemato-Oncology
Rheumatology
Others
Plasma Fractionation Market, by End User
Plasma Fractionation Market, by Geography
North America
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117
Amidst this crisis, Meticulous Research is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/custom-research
Related Reports:
Blood Screening Market by Product (Reagents & Kits, Instruments, Software), Technology (NAAT [Real-time PCR], ELISA [CLIA, FIA, CI], Rapid Tests, Western Blotting, NGS), and End User (Blood Banks, Hospitals, Laboratories) - Global Forecast to 2027
https://www.meticulousresearch.com/product/blood-screening-market-5164
Vaccines Market by Indication (Influenza, Rotavirus, DTP, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccines, Live Attenuated Vaccines), and Valence (Multivalent, Monovalent Vaccines) - Forecast to 2028
https://www.meticulousresearch.com/product/vaccines-market-5076
Research Antibodies and Reagents Market by Product {Antibodies [Type (Primary, Secondary), Production, Source, Research Area (Oncology, Neurology)], Reagents}, Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027
https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055
Plasmapheresis Market Size by Product Type (Instruments and Disposables), by Technology (Centrifugation and Membrane Filtration), Application (Therapeutic Plasmapheresis and Source Plasma Collection), End User (Biopharmaceutical Companies, Hospitals and Clinics, Others) - Global Forecasts to 2022
https://www.meticulousresearch.com/product/plasmapheresis-market-3092
About Meticulous Research
Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since its inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding, California, 96001, U.S.USA: +1-646-781-8004Europe : +44-203-868-8738APAC: +91 744-7780008Email- sales@meticulousresearch.com Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/366/plasma-fractionation-market-2027
- Alumnus discovers passion for immunology, teaching at Mercer - Mercer University - March 15th, 2025 [March 15th, 2025]
- The future of immunology - Johnson & Johnson - March 5th, 2025 [March 5th, 2025]
- Immunotherapys Sweet Future: Wrapping up AACR IO 2025 With Glyco-immunology - American Association for Cancer Research (AACR) - March 5th, 2025 [March 5th, 2025]
- J&J receives three CHMP recommendations for immunology and oncology indications - PMLiVE - March 5th, 2025 [March 5th, 2025]
- Greater Austin Allergy, Asthma & Immunology now open in the Shops at the Galleria - Community Impact - March 5th, 2025 [March 5th, 2025]
- As dengue spreads, researchers discover a clue to fighting the virus - La Jolla Institute for Immunology - February 25th, 2025 [February 25th, 2025]
- Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business... - February 25th, 2025 [February 25th, 2025]
- PhD candidate Jesse Lehman receives Kirschstein Award to study immunology - UMass Medical School - February 25th, 2025 [February 25th, 2025]
- Cross-priming in cancer immunology and immunotherapy - Nature.com - February 3rd, 2025 [February 3rd, 2025]
- Sanofi Happy To Spend To Hit Immunology Top Spot - News & Insights - February 3rd, 2025 [February 3rd, 2025]
- The Converging Therapeutic Landscape of Oncology and Immunology: Accelerating Innovation in Biotech - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- VC Firm Foresite Capital Dishes on Biotech Innovation in China, Opportunities in Immunology - MedCity News - January 23rd, 2025 [January 23rd, 2025]
- Immunology - The Scientist - January 23rd, 2025 [January 23rd, 2025]
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]